Nuvation Bio Inc.NUVB
Recorded
Nuvation Bio Inc. Cantor Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Period 0Duration30 min
Key takeaways
- Nuvation Bio launched Ib Trosi, a ROS1 inhibitor, over a year ago with a 90% response rate and a 50-month duration of response in the first-line setting, unmatched in oncology.
- Ib Trosi has an overall discontinuation rate of 6.5%, with very low discontinuations due to adverse events, making it highly tolerable.
- The epidemiology indicates 3,000 new ROS1 patients annually by DNA testing, with a potential market exceeding $4 billion due to revenue stacking from long duration of response.
- In the first year of launch, Nuvation captured about 20% of the frontline ROS1 market, growing from 70 to 140 first-line patients per quarter.
- Nuvation's IDH1 inhibitor, SAPO, for gliomas shows promising three-year follow-up data with a 79% non-progression rate and a 52% response rate, outperforming competitor vorasidenib.
- Nuvation is conducting four clinical trials targeting all glioma subtypes, with some trials expected to read out as early as 2027 and others by 2029.
- The company has $700 million in cash, sufficient to reach profitability.
- Ib Trosi has shifted to 85% frontline patient mix, with potential to double sales by converting I/O chemo patients and increasing testing in community centers.
- Nuvation is actively educating physicians, patient advocacy groups, and organizations to increase adoption of ROS1 agents.
- GSK's ROS1 agent received CNS warnings and adverse events that may limit its use, positioning Ib Trosi as the only ROS1 agent without CNS warnings and with superior efficacy.
- Nuvation believes physician experience with Ib Trosi is key to entrenchment in the frontline setting, with many physicians re-prescribing the drug due to positive experience.
- SAPO shows better results than vorasidenib in both high-grade and low-grade gliomas, possibly due to immune-related effects beyond IDH1 inhibition.
- Nuvation plans to discuss with FDA the use of tumor growth rate as an approval endpoint, which may capture clinical benefit beyond formal response criteria.
- The post-vorasidenib failure study is enrolling patients to show SAPO activity in patients with no current treatment options.
- Nuvation expects to complete enrollment of 40-50 patients in the grade 3 oligodendritic glioma study by 2027.
- Nuvation believes it may be the last company able to conduct a placebo-controlled low-grade glioma study, potentially securing market exclusivity for SAPO.
- The company prefers later-stage business development opportunities with compelling data and unmet need, aiming to fill gaps before 2029 approvals.
- Nuvation also has an early-stage drug-drug conjugate platform and a marketed product, Ib Trosi, with SAPO in advanced development.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring